Bioidentical Hormones Research on Doctors’ Decisions

Bioidentical Hormones for Menopause: What Research on Doctors’ Decisions Reveals

A new survey of 600 obstetricians and gynecologists in Turkey examined how a regulatory action influenced their treatment choices for menopausal hormone therapy (MHT). The findings show that a doctor’s personal views on compounded “bioidentical” hormones, and their commitment to patient preference, often weigh more heavily than official warnings in shaping clinical practice.

Doctors’ Personal Views Outweigh Regulatory Awareness

The survey, published in Menopause, created a Regulatory Awareness Score based on doctors’ recognition and understanding of a U.S. Food and Drug Administration (FDA) communication. This communication addressed the risks of compounded bioidentical hormone therapy. However, this awareness did not independently predict whether a doctor said they changed their routine approach. After adjusting for other factors, the odds ratio was 0.89, meaning there was no significant link.

What did drive reported change? The strongest factor was a clinician’s favorable perception of compounded BHT itself. Doctors with positive views were 85% more likely to report altering their practice. Using a standard clinic protocol made doctors 50% more likely to report a change. A stronger focus on patient preference increased the odds by 21%, and seeing a higher volume of menopause patients also had a small but significant effect.

The Latin American Expert Stance on Androgens and Compounded Hormones

This research aligns with a separate, definitive position statement from the Latin American Association of Gynecological Endocrinology (ALEG). Published in Climacteric, the ALEG statement clarifies the role of androgen therapy—which includes hormones like testosterone—for midlife and older women. The experts confirm that for women with hypoactive sexual desire disorder (HSDD), testosterone can be an effective, evidence-based treatment when conventional estrogen therapy hasn’t worked.

However, the society draws a sharp, evidence-based line regarding formulation. They explicitly advise against the use of compounded bioidentical hormone therapy. The reasons are clear: these custom-mixed preparations lack rigorous testing for safety, efficacy, dosage consistency, and long-term health impacts. They are not equivalent to FDA-approved or similar internationally approved hormone products, which undergo strict manufacturing and clinical scrutiny.

How “Bioidentical” Marketing Creates Confusion

The term “bioidentical” is often used to imply a natural or safer alternative to conventional hormone therapy. Scientifically, it refers to hormones that are chemically identical to those the human body produces, like estradiol and progesterone. Many FDA-approved MHT products contain these exact bioidentical molecules. The critical distinction lies not in the molecule, but in the source and preparation.

Compounded BHT is mixed individually in pharmacies, not subject to batch testing or large-scale clinical trials. This can lead to variable potency, contamination risks, and untested combinations. A patient may believe she is getting a “natural” solution, but she is receiving a product with an unverified safety profile. The ALEG statement and the FDA’s concern focus on this specific, unregulated compounding process, not on bioidentical hormones as a class.

Shared Decision-Making in a Complex Landscape

The survey by Cömert EH and colleagues reveals that patient preference is a powerful motivator for clinicians. This underscores the real-world challenge of menopause care: patients seeking relief from disruptive symptoms often encounter persuasive marketing for compounded hormones. Doctors, aiming to partner with patients, may feel pressured to accommodate these requests even when aware of the risks, especially if they hold some favorable views themselves.

This creates a counseling priority. The evidence suggests effective care involves explaining the difference between approved bioidentical hormones and compounded versions, discussing the robust evidence behind approved therapies for symptoms and bone health, and honestly outlining the unknown risks of untested compounds. For symptoms like low libido where testosterone may be indicated, the conversation should focus on approved transdermal options, not compounded formulations.

Frequently Asked Questions

Are bioidentical hormones safer than standard hormone therapy?

Not necessarily. Many standard, FDA-approved products contain bioidentical hormones (like estradiol). The safety concern from major medical societies is specifically about compounded bioidentical hormones, which are not tested for consistent dosage, purity, or long-term safety.

Why would a doctor still prescribe compounded hormones if there are warnings?

The survey found a doctor’s personal positive perception of compounded BHT was the strongest factor in their reported practice. Some may prioritize a patient’s strong preference for a customized formula, despite the lack of evidence, highlighting the complexity of shared decision-making.

What is the approved alternative for low sexual desire in menopause?

According to the ALEG position, for diagnosed hypoactive sexual desire disorder (HSDD), evidence supports the use of approved transdermal testosterone therapy after trying conventional estrogen therapy. They firmly recommend against using compounded testosterone preparations.

I have breast cancer history. What does this mean for me?

Hormone therapy decisions are highly individual and critically important for breast cancer survivors. You should have a detailed discussion with your oncologist and menopause specialist. For information on the specific cognitive and menopausal challenges faced by young breast cancer survivors, you can read our article on Young Breast Cancer Survivors Face Menopause Challenges.

Sources:
https://pubmed.ncbi.nlm.nih.gov/42376873/
https://pubmed.ncbi.nlm.nih.gov/40919649/
https://pubmed.ncbi.nlm.nih.gov/40109076/